Cancer stem cells (CSCs) of head and neck squamous cell carcinoma (HNSCC) are defined by high self-renewal and drug refractory potential. Involvement of Wnt/β-catenin signaling has been implicated in rapidly cycling cells such as CSCs, and inhibition of the Wnt/β-catenin pathway is a novel approach to target CSCs from HNSCC. In this study, we found that an antagonist of FrzB/Wnt, the secreted frizzled-related protein 4 (sFRP4), inhibited the growth of CSCs from two HNSCC cell lines, Hep2 and KB. We enriched the CD44 + CSC population, and grew them in spheroid cultures. sFRP4 decreased the proliferation and increased the sensitivity of spheroids to a commonly used drug in HNSCC, namely cisplatin. Self-renewal in sphere formation assays decreased upon sFRP4 treatment, and the effect was reverted by the addition of Wnt3a. sFRP4 treatment of spheroids also decreased β-catenin, confirming its action through the Wnt/β-catenin signaling pathway. Quantitative PCR demonstrated a clear decrease of the stemness markers CD44 and ALDH, and an increase in CD24 and drug-resistance markers ABCG2 and ABCC4. Furthermore, we found that after sFRP4 treatment, there was a reversal in the expression of epithelial to mesenchymal (EMT) markers with the restoration of the epithelial marker E-cadherin, and depletion of EMT-specific markers twist, snail and N-cadherin. This is the first report demonstrating that the naturally occurring Wnt inhibitor, sFRP4, can be a potential drug to destroy CSC-enriched spheroids from HNSCCs. The repression of EMT and the decrease in stemness profile further strengthen the use of sFRP4 as a potent therapeutic against CSCs.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide. 1 Mortality from HNSCC is high because of distant metastases and the emergence of therapyresistant tumors. Prognosis of HNSCC is determined by the degree of lymphatic invasion and metastasis at diagnosis. 1 The standard of care for patients with HNSCC includes primarily platinum-based chemotherapeutic drugs, surgery and radiotherapy. 2 Despite this, the 5-year survival rate for these patients has still been in the range of 50 − 60% for the last 3 decades. 3 Cancer stem cells (CSCs), a small population of cells in most tumors, support tumor growth through their ability to self-renew and differentiate into heterogeneous tumor tissue. CSCs are typically resistant to radiation therapy and standard cytotoxic agents, which results in their enrichment and in the consequent recurrence of refractory tumors. After initially being identified in leukemia, 4 they have been found in many solid tumors. CSCs have been identified in human HNSCCs using markers such as CD133 and CD44, and by aldehyde dehydrogenase (ALDH) activity. 5 The presence of CSCs in HNSCC has been reported in many studies and has been comprehensively reviewed by Minnelli and Gallo. 6 The HNSCC CSCs reside in perivascular niches in the invasive front, where endothelial cells contribute to their survival and function.
Targeting key signaling pathways that are active in CSC selfrenewal is one approach to cancer therapy. Abnormal activation of the Wnt/β-catenin signaling pathway has been described in a wide variety of human cancers and in CSCs, and has already been demonstrated in HNSCCs. 7 Wnt dysregulation has a role in inducing epithelial to mesenchymal transition (EMT) transcription factors Twist and Snail. [8] [9] [10] CSCs from hepatic carcinoma cell lines exhibited enhanced chemoresistance to cisplatin, which was reversed by lentiviral microRNA knockdown of β-catenin.
11 Similar studies have demonstrated that the Wnt/β-catenin signaling pathway was also able to confer chemoresistance to 5-fluorouracil and doxorubicin. 12, 13 Activation of the Wnt pathway, by the Wnt receptor frizzled-1, induced expression of the multiple drugresistance gene MDR1 and promoted resistance to doxorubicin in chemoresistant neuroblastoma cells. 13 In ovarian CSCs, ABCG2 was shown to mediate cisplatin and paclitaxel resistance, which was reversed by β-catenin small interfering RNA knockdown. 14 In this study, we investigated the effect of the naturally occurring protein secreted frizzled-related protein 4 (sFRP4), which is an inhibitor of Wnt signaling, on CSC-enriched spheroid cells from two HNSCC cell lines. We examined the ability of sFRP4 to chemosensitize spheroids with commonly used therapeutic drugs and studied CSC-specific properties such as self-renewal, the expression of CD44-positive cells and the ability to form spheres in culture. To explore the underlying molecular mechanism of sFRP4, we examined the Wnt/β-catenin signaling pathway, changes in the EMT profile with relation to sFRP4 and the expression of drug-resistance markers. We identified that sFRP4 enhanced the chemosensitivity of CSC-enriched cells by inducing apoptosis, reducing EMT and decreasing stemness properties. Our findings are relevant in the context of designing drugs targeting CSCs, as sFRP4 is a natural Wnt antagonist acting only on cells having dysregulated Wnt/β-catenin signaling. These studies identify sFRP4 as a key Wnt antagonist that can regulate CSC maintenance and chemoresistance, which can lead to better targeted modes of cancer therapy.
MATERIALS AND METHODS

Cell lines
The two cell lines Hep2 (laryngeal carcinoma) and KB (tongue carcinoma) used in this study were purchased from the National Center of Cell Sciences, Pune, India, and cultured and maintained in DMEM/F-12 and DMEM-LG (Gibco, Grand Island, NY, USA; 1:1) containing 1X GlutaMax (Life Technologies, Carlsbad, CA, USA), 10% fetal bovine serum (Hyclone), and 100 U ml − 1 PenStrep (Life Technologies). Normal non-tumorigenic mouse embryonic fibroblasts were isolated from mouse embryo day e10.5 and cultured in DMEM-KO medium containing 1X GlutaMax (Life Technologies), 10% fetal bovine serum (Hyclone, Logan, UT, USA) and 100 U ml
PenStrep (Life Technologies). Serum-free medium for sphere culture was performed in basal medium (DMEM/F-12+DMEM-LG) with 100 U ml
PenStrep, 2 mM GlutaMAX and containing 20 ng ml − 1 each of epidermal growth factor, basic fibroblast growth factor (R&D Systems, Minneapolis, MN, USA) and leukemia inhibitory factor (Chemicon, Temecula, CA, USA). All cells were cultured at 37°C in a humid incubator with 5% CO 2 . CSC populations were enriched by plating a single-cell suspension of Hep2 and KB cells at 5000 cells ml − 1 in serum-free medium on non-adherent six-well plates (BD Biosciences, San Jose, CA, USA) as reported previously. 15 The medium was replenished once in 2 days by centrifuging for 3 min at 450g at room temperature, aspirating the medium and replacing it with fresh stem cell medium till the spheres were 4120 μm in size, as observed using an inverted phase contrast microscope (Nikon-Eclipse TE 2000-S, Kanagawa, Japan). Spheres were then characterized for the expression of CSC markers CD44 and ALDH by flow cytometry and quantitative PCR.
After identifying for CSC enrichment of the spheres, spheroids were used for further analysis.
Proliferation assays
MTT. The TACS MTT assay kit (R&D Systems) was used according to the manufacturer's protocol to measure cell metabolic viability.
Hep2 and KB spheroids were cultured in non-adherent serum-free medium conditions (10 000 cells ml − 1 ) in 96-well plates. Drugs used were sFRP4 (250 pg ml − 1 ), cisplatin (10 mM) and doxorubicin (50 μg ml − 1 ). The following treatment groups were examined: sFRP4 (S), cisplatin (C), sFRP4 +cisplatin (S+C), doxorubicin (D) and sFRP4+doxorubicin (S+D) for a treatment time of 24 h. After drug treatment, an MTT assay was performed and the plates were read at 595 nm using a Victor 3 Multilabel Plate Reader (Perkin-Elmer, Waltham, MA, USA). As the combination of S+C was the most effective, subsequent analysis was performed using C and S+C.
5-Bromodeoxyuridine assay. Hep2 and KB spheroid cultures were subjected to the following drug conditions: sFRP4 250 pg ml − 1 (S), cisplatin 10 mM (C) and a combination of sFRP4 and cisplatin (S+C). The same drug treatment was performed for the remainder of the experiments. Hep2 and KB spheres were treated with various drugs, and cell proliferation was measured using the BrdU Cell Proliferation Assay Kit (Cell Signaling Tech, Danvers, MA, USA) according to the manufacturer's protocol. Plates were read at 450 nm using a Victor 3 Multilabel Plate Reader (Perkin-Elmer).
Secondary sphere-forming assay Primary spheres were obtained by plating 10 000 cells ml
, under serum-free medium conditions, in ultra-low adherence six-well culture plates. On day 2, primary spheres were subjected to drug treatment as indicated. After treatment, the primary spheres from each condition were disrupted into single-cell suspensions and were replated for secondary sphere formation under each condition. The secondary spheres were observed for morphology and the total number of spheres were counted, together with the number of spheres of different sizes using a bright field phase contrast microscope (Nikon-Eclipse TE 2000-S) and photographs were taken using a Qimaging-QICAM-fast 1394 (Surrey, BC, Canada).
Caspase assay
After treatment of Hep2 and KB spheroids with the various drug treatments, the activity of apoptosis-inducing caspase-3 was assayed using the EnzChek DEVD-CHO Caspase3 Assay Kit (Invitrogen, Carlsbad, CA, USA), which provides a fluorescent substrate R110. Intensity of the fluorescence is correlated with an increase in caspase-3 activity, and the fluorescence intensity was measured using a Victor 3 Multilabel Plate Reader at 485/535 nm (Ex/Em). Table 1 . Primer sequences for apoptosis-and stemness-related genes
Genes
Primers Base pair Annealing temperature,°C
183 56
188 55
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Semiquantitative reverse transcription-PCR
Total RNA was extracted from Hep2 and KB spheroids after drug treatment using the RNeasy Plus Mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer's instructions. Total RNA was reverse-transcribed using SuperScript III First-Strand Synthesis System (Invitrogen). RNA (1 μg) was mixed with 1 μl Oligo dT (50 μM) and 1 μl of dNTP (10 mM), made up to 13 μl with diethylpyrocarbonate-treated water and heated at 65°C for 10 min, followed by incubation on ice. After primer hybridization, 7 μl reaction volume containing 5X first-strand buffer, RNase OUT (40 Uμl − 1 ), 0.1 M dithiothreitol and Superscript III were added to the RNA and subjected to thermocycling (25°C, 5 min; 50°C, 60 min; 70°C, 15 min) in a Veriti 96-well thermal cycler (Applied Biosystems, Carlsbad, CA, USA). Qualitative expression of markers for CSC, apoptosis, drug resistance and EMT (primers from Sigma (St Louis, MO, USA), sequences as indicated in Tables 1 and 2) were analyzed by PCR (95°C 30 s; annealing temperature, 30 s; 72°C 30 s for 40 cycles) in a Veriti 96-well thermal cycler. Products were resolved in 1.5% agarose gel electrophoresis and detected using ethidium bromide. Integrated density values were calculated using Alpha manager.
Real-time quantitative reverse transcription-PCR
The mRNA expression of different genes obtained qualitatively was further quantified using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) in a real-time PCR system. cDNAs and gene-specific primers were mixed with 2X iQ SYBR Green Supermix (Bio-Rad), and dispensed on a MicroAmp Optical 8-Tube Strip. Fluorescence shift was observed using a 7500 Real-time PCR system (Applied Biosystems). The reaction parameters were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. PCR products were verified by melting curves. The relative abundance of mRNAs was obtained using the comparative cycle threshold method and was normalized to the housekeeping control gene GAPDH, and ΔCT was calculated by subtracting the CT value of the GAPDH reference gene from that of each gene. Results were also expressed as fold changes (ΔΔCT) in the mRNA levels of a gene compared with the treated or untreated samples.
Western blotting
Protein expression levels of β-catenin, the central component of canonical Wnt signaling, were determined by Western blotting. Equal amounts of cell lysate were resolved by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA) and detected with antibodies targeting either anti-human mouse β-catenin mAbs at 1:500 dilution (R&D Systems) or anti-human mouse actin mAbs at 1:500 dilution (Millipore). Rabbit anti-mouse horseraddish peroxidase-linked secondary antibodies (1:3000) were used to bind to the primary antibody. The blot was developed with enhanced chemiluminescence reagent (Pierce, Rockford, IL, USA), and images were captured using AlphaImager (San Leandro, CA, USA).
Statistical analysis
Data represent mean and s.e. from experiments done in triplicate, and were determined with a two-side Student's t-test, and the significant difference level was established at Po 0.05.
RESULTS
sFRP4 inhibits HNSCC spheroids at low dosage and increases the response with chemotherapeutics via the apoptotic pathway To investigate the effect of sFRP4 on CSC-enriched cells, we used two HNSCC cell lines. The effect of sFRP4 on CSC-enriched cells from the KB and Hep2 cell lines was tested with MTT and 5-bromodeoxyuridine assays. It was observed that sFRP4 inhibited proliferation and, in combination with commonly used oral cancer chemotherapeutics such as cisplatin and doxorubicin, inhibition was more pronounced. The combination of cisplatin and sFRP4 effectively reduced the viability to 25% in both Hep2 and KB spheroids (Figure 1a and b) and hence, cisplatin was used in the subsequent studies. The caspase-3/7 assay showed induction of apoptosis by the activation of caspase 3/7 enzyme and was maximal in the S+C treated cells (Figure 1c ).
Self-renewal and CSC-specific markers of Hep2 and KB spheroids reduced by sFRP4 One of the strategies used for the enrichment of CSCs and for the analysis of self-renewal, a hallmark property of CSCs, is to study the formation of clonogenic spheres and secondary sphere formation. We have previously reported the formation of secondary spheres by the CSCs enriched from glioma cell lines. 16 We show that addition of sFRP4, and in combination with cisplatin, drastically disrupted the formation of secondary spheres (Figure 2a) and there was no clonogenic expansion. Expression of the CSC-specific marker CD44 was reduced markedly in sFRP4-treated and in sFRP-Cis-treated Hep2 and KB spheroids, as demonstrated by immunohistochemistry (Figure 2b) . Flow cytometry showed a modest decrease in CD44-positive cells (Figure 2c ).
Inhibition by sFRP4 is through the Wnt/β-catenin signaling pathway As sFRP4 is a known antagonist of the Wnt pathway, we used the Wnt agonist, Wnt3a, and the GSK3β inhibitor, lithium chloride, in our assay to see their effect on sFRP4-mediated inhibition. In sFRP4-treated cells, Wnt3a and LiCl increased proliferation of Hep2 and KB spheroids and reversed the inhibition produced by sFRP4 (Figure 3a) . Non-tumorigenic fibroblastic cells, mouse embryonic fibroblasts, however, showed no effect upon various drug treatments. Further confirmation that the mode of action of sFRP4 is through the Wnt/β-catenin axis was provided by Western blotting of sFRP4 and cisplatin-treated Hep2 spheroids. It was seen that, after sFRP4 and cisplatin treatment, there was a marked reduction of β-catenin protein, suggesting that sFRP4 abolishes accumulation of β-catenin via the Wnt/β-catenin signaling pathway (Figure 3b) . Expression study of apoptotic genes, stemness genes, epithelial to mesenchymal (EMT) and drug-resistant markers by semiquantitative and quantitative reverse transcription-PCR. Cyclin D1, Xiap, MDM2 and Ki67 levels, as represented by semiquantitative PCR (a) quantified by quantitative PCR (b), were reduced in S, C and S+C treated Hep2 and KB spheroids, and the expression of apoptosis-inducing genes Bax and p21 increased upon drug treatment. CSC-associated genes CD44 and ALDH decreased, but CD24, a negative CSC marker, was shown to increase in both Hep2 and KB CSCs (a, b1 and b2). EMT-specific markers Twist and Snail decreased. Mesenchymal to epithelial switch was demonstrated by the decrease in N-cadherin and increase in E-cadherin (a, b1 and b2). Decreased levels of drug-resistance markers, ABCG2 and ABCC4 (a, b1 and b2), were seen in the drug-treated spheroids. A similar trend was observed in both Hep2 and KB spheroids. 'U' represents the untreated control. Results are the mean ± s.d. of two independent experiments performed in triplicate (*Po 0.05, **P o0.01, n = 3). sFRP4 upregulates apoptotic genes and represses stemness genes We studied the expression of genes such as Cyclin D1, a regulator of cell cycle progression, Bax, a key promoter of apoptosis and p21, a cyclin dependent kinase inhibitor, in Hep2 and KB spheroids by quantitative PCR following treatment with sFRP4 and cisplatin. We found that treatment with sFRP4 in combination with cisplatin, activated Bax and p21 gene expression but reduced the expression of Cyclin D1, proliferation markers Ki67 and MDM2 and inhibitor of apoptosis, xIAP (Figure 4b) . As the CSC-enriched cells had high levels of CSC-associated genes such as CD44 and ALDH, we analyzed the expression of these genes under the various drug treatments. We found that all these genes were downregulated in sFRP4-and cisplatin-treated spheroids derived from both Hep2 and KB cell lines (Figure 4a and b) . sFRP4 downregulated EMT-promoting genes and drug-resistance genes EMT, a typical trait of CSCs, is accompanied by a shift in cadherin expression from E-cadherin to N-cadherin. We found a reversal of EMT with the accumulation of E-cadherin and a reduction in N-cadherin levels in sFRP4, cisplatin and combination treated Hep2 and KB spheroids. In addition, we observed that the molecular markers implicated in EMT, such as twist and snail, were downregulated in spheroids treated with sFRP4 and cisplatin (Figure 4a and b) . The expression of the ABC genes ABCG2 and ABCC4, which are involved in drug efflux and are normally upregulated in CSCs, were also analyzed and we observed that their expression was reduced in sFRP4-cisplatin-treated Hep2 spheroids (Figure 4a and b) .
DISCUSSION
CSCs have remained an elusive and ever changing population present within tumors. As their isolation from tumor tissue is a challenge, enrichment of CSCs from cell lines is an ideal alternative for the testing of novel drugs that can inhibit these highly refractory and chemoresistant populations. Owing to their closeness to normal stem cells, CSCs rely on pathways that govern development, self-renewal and cell fate. These pathways are largely regulated by three signaling programs; namely, the Wnt, 17, 18 Notch 19, 20 and Hedgehog pathways. 21, 22 Aberrant Wnt/β-catenin signaling has been implicated in numerous malignancies attributed to the constitutive hyperactivation of the pathway. A level of regulation in normal cells that keeps β-catenin levels in check is the presence of antagonists of the Wnt pathway, which either bind to Wnt ligands or to Wnt receptors, or both. 23 The sFRPs are structurally related to the frizzled (Fz) receptors and are antagonists of Wnt signaling functioning by interacting with both Wnts and Fz receptors. 24, 25 It has been shown that sFRP4 is involved in the regulation of apoptosis, proliferation, tissue formation and tumor growth. [26] [27] [28] [29] In this study, we show that similar to our earlier report on glioma CSCs, 14 sFRP4 was effective in improving the chemoresponse of CSC-enriched spheroids from HNSCC cell lines to the commonly used chemotherapeutic cisplatin.
As the sFRP4-mediated inhibition operates through the Wnt/β-catenin signaling pathway, we could demonstrate that the inhibition by sFRP4 was rescued by the addition of a Wnt ligand such as Wnt3a. Inhibition by sFRP4 is relayed downstream by the activation of GSK3β kinase and by the phosphorylation of β-catenin. We could show that LiCl (an inhibitor of GSK3β kinase) could also remove the inhibition brought about by sFRP4. Activation and accumulation of β-catenin in the cytoplasm will result in the nuclear translocation of β-catenin. In the nucleus, β-catenin binds to the transcription factors of the T-cell factor, a lymphocyte-enhancing factor family, upregulating genes associated with proliferation and migration such as cycD1, c-myc and cox2. Our observations of downregulation of the proliferationassociated gene, cycD1, together with an increase in the Wntregulated apoptotic genes, Bax and p21, indicate the initiation of the apoptotic process by suppression of Wnt signaling.
Wnt activity determines stemness and self-renewal of CSCs from colon cancers 30 and breast cancers, 31 and WNT pathway activation is significantly higher in breast CSCs, whereas normal stem-like cells have lower levels of WNT signaling. 32 Our data clearly indicate that sFRP4 is able to reduce the sphere-forming and selfrenewal ability of the CSC-enriched HNSCCs. Furthermore, HNSCCspecific CSC markers such as CD44 and ALDH are downregulated by sFRP4 treatment. Pancreatic CSCs, identified by CD44 + CD24 − and ALDH expression, have been shown to be sensitized to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis by sulforaphane, which acts by dysregulating antiapoptotic nuclear factor-κB signaling. 33 A similar mechanism may govern the dramatic reduction in self-renewal, clonogenicity and CSC marker expression caused by sFRP4 treatment in conjunction with chemotherapeutic drugs in HNSCC spheroids.
EMT is a reversible dedifferentiation process converting epithelial cancer cells to dedifferentiated cells with mesenchymal properties and is characterized by the loss of epithelial features and the acquisition of mesenchymal traits. 34, 35 The EMT transcription factors ZEB1/2 have been shown to be overexpressed in CSC-like cells in HNSCCs and are linked to decreased survival rates, increased sphere formation, CD44 + cells, tumor growth and metastasis. 36 Loss of E-cadherin is the fundamental event in EMT. E-cadherin is a tumor invasion suppressor and is downregulated in most carcinomas, while N-cadherin, an invasion promoter, is frequently upregulated in the EMT switch. Upon EMT conversion, epithelial cells lose cell-cell adhesion and cell polarity, and have decreased expression of E-cadherin and an increase in mesenchymal cell markers vimentin, fibronectin, N-cadherin, α-smooth muscle actin, as well as increased activity of matrix metalloproteinases (MMPs) such as MMP-2, -3 and -9, which are associated with an invasive phenotype. 36 The reversible downregulation of E-cadherin (encoded by CDH1) involves either hypermethylation of the CDH1 promoter or repression by EMT-inducing transcription factors. 35, 37 The loss of E-cadherin releases β-catenin into the cytosol and elicits activation of the canonical Wnt signaling pathway. 36 An increased expression of E-cadherin over N-cadherin, which we observed following the sFRP4 treatment, indicates a reversal of EMT. This phenomenon is further corroborated in our study by the downregulation of Twist and Snail, which are transcriptional repressors of E-cadherin. 36 ABC drug transporters are overexpressed in both normal stem cells and many CSCs as drug efflux pumps. 38, 39 Of the ABC transporters examined, we found a decrease in the expression of ABCG2 and ABCC4 in sFRP4-and drug-treated spheroids. ABCG2 is an important member of the ABC transporter family, is one of the potential markers of CSCs that facilitates the mechanism of multidrug resistance and is an important determinant of the CSC side population phenotype. 40, 41 The CSC assay technique used in this study, which utilizes CSC enrichment in stringent low-attachment, serum-free culture, is an effective platform for multiple drug screening. We have shown that sFRP4, an endogenously expressed Wnt antagonist, is able to inhibit CSC growth and render these cells more responsive to chemotherapeutics. sFRP4 has no inhibition in normal noncancerous cells because these cells have a low level of Wnt signaling. Hopefully, this study could provide an impetus for the emergence of sFRP4 as a viable inhibitor of CSCs in many tumors.
